chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report was received from a physician, via company representative, and refers to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, concomitant therapies, drug reactions or allergies were not reported. On 31-AUG-2015, the patient was vaccinated with an improperly stored PNEUMOVAX 23 10 PK, lot # L002310, expiration date 08-JUL-2016, at a dose of 0.5 ml, (route and anatomical location of administration were unspecified). The vaccine underwent a total temperature excursion, of 144 hours. The lowest recorded temperature was 27 Fahrenheit degrees (-2.777777778 Celsius). The vaccine status was reported as "in excursion" The vaccine storage criteria and the vaccine excursion were reported as "Refrigerator(R)". No adverse effects were reported. No Product Quality Complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
The second the person gave me the shot my index finger went numb, stiff and my range of motion decreased.  Within less than 24 hours day my whole hand and lower arm were stiff, numb,  painful, and tingling. I also have overall weakness and doing basic tasks like writing essays for school has become painful and difficult. My hand is stiff and looks like a claw. While it has gotten a little better after taking medications that my doctor prescribed my fingers are still weak stiff, numb, tingling, and painful.  The vaccine was administered too far up and too far to the left which has most likely caused nerve damage.  There is also a small bruise at the injection site and the injection is still visible 5+ days later. This could have been prevented through better training of health officials working at state-run vaccine sites. I hope this hasn't caused lasting damage.
The day of the vaccine, I experienced fatigue and sleepiness. The day after the vaccine, I awoke with muscle soreness and stiffness particularly in the right side of my neck. That afternoon, I also had chills, fever, fatigue and nausea.  This lasted for apx 12 hours.  36 hours after the vaccine, I began having severe lymphnoid pain in my left armpit.  The paid came on quickly and slowly dissipated over a period of 5 days.
Child was being held by mother, when I injected the child she jerked away quickly, causing the syringe to pop out and about half of the vaccine liquid to squirt out.  RPH called Pfizer and was referred by them to contact the CDC  to inquire what steps we need to take to ensure child gets her proper dosage. CDC  quoted the  Covid 19 administration errors and deviations guidelines ( dated 11-08-2021) which state to repeat the dose immediately and that a half-dose may be given.  RPH contacted the father who was concerned with the patient receiving too high a dose of vaccine.  Patient's father requested that a third of the pediatric dose be administered instead the full or half-dose.  RPh complied with the parent's request and showed the vaccine dose to the mother when the patient returned to the store on the same day.  Patient received a second injection of 0.05ml which is 1/4 of the dose and the mother was satisfied and agreed with the dosing of the second injection.
Substernal chest pain approx three days after booster shot.  Admitted to a local Medical Center for Myocarditis.  Spent 3 days in hospital then released under Dr care.  Still undergoing follow-ups with additional perscriptions
muscle aches/ Myalgia; Serum reaction; possible post herpetic neuralgia; Headache; skin discomfort; skin sensation; fatigue; injection site soreness; injection site redness; This case was reported by a other health professional via call center representative and described the occurrence of muscle pain in a 58-year-old male patient who received Herpes zoster (Shingrix) (batch number 494PR, expiry date 13th September 2021) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on an unknown date, no adverse event to the 1st dose).   On 5th June 2019, the patient received the 2nd dose of Shingrix (intramuscular). On 6th June 2019, 1 days after receiving Shingrix, the patient experienced muscle pain, serum reaction, post herpetic neuralgia, headache, skin discomfort, sensitive skin, fatigue, injection site pain and injection site erythema. The patient was treated with paracetamol (Tylenol). On an unknown date, the outcome of the muscle pain, post herpetic neuralgia, headache, skin discomfort, sensitive skin and fatigue were not recovered/not resolved and the outcome of the serum reaction, injection site pain and injection site erythema were unknown.   It was unknown if the reporter considered the muscle pain, serum reaction, post herpetic neuralgia, headache, skin discomfort, sensitive skin, fatigue, injection site pain and injection site erythema to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix in right arm. The health care professional stated that the patient reported skin sensation/discomfort possible post herpetic neuralgia but no rash, muscle aches, headache, mild fatigue following 2nd dose of Shingrix.  The patient took Tylenol which helped to lessen the symptoms but the symptoms still had not resolved. The patient also experienced injection site soreness and redness. The physician's diagnosis was myalgia and other serum reaction due to vaccination initial encounter. The reporter had consented to follow up. There was a discrepancy in outcome of the events, in the source document outcome of the events were reported as recovering/ resolving, but it was reported as not recovered/ resolved. The outcome kept as reported.
Initial unsolicited report received from a non-healthcare professional (office staff) on 13 November 2015. This case involves a male patient who was vaccinated with a dose of FLUZONE QIV) (batch number UI431AB, expiration date 30 June 2016, route, cycle in series and site of administration was not reported) on an unspecified date. Patient medical history and concomitant medications were not reported. On unspecified date, following the vaccination, the patient experienced itching, hives, throat closing, chills and anaphylactic. Lab data and corrective treatments were not reported. Outcome of events was not reported. Upon internal review, the case was considered to be serious due to important medical events: anaphylactic reaction, itching and hives. List of documents held by sender: none.; Sender's Comments: This is poorly documented medically not confirmed case. In which the office staff reported as anaphylactic reaction after administration of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED. However, investigation results ruling out a concurrent infection and other etiologies would be helpful to further assess this case. Based on the information the role of the vaccine cannot be assessed.
Patient came in for his "1st Moderna shot" on Saturday 7/31/21. He calls on Monday 8/2/21 complaining of a very sore arm, much more sore than his 1st 2 shots. He admitted that he got 2 shots from a health facility, presented at the pharmacy stating he did not have insurance. Patient calls again on Tuesday 8/3/21 that his arm is in a lot of pain so I suggested he go see a MD about it sooner rather than later.
Booster  was pfizer  Modena the Covid 19 vaccine can not sleep then can not wake up felt bad for one week
Big circle at the site of injection; Warm to the touch circle at the site of injection; Red circle at the site of injection; This spontaneous case was reported by a consumer and describes the occurrence of ADMINISTRATION SITE INDENTATION (Big circle at the site of injection), VACCINATION SITE WARMTH (Warm to the touch circle at the site of injection) and VACCINATION SITE ERYTHEMA (Red circle at the site of injection) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Mar-2021, the patient experienced ADMINISTRATION SITE INDENTATION (Big circle at the site of injection), VACCINATION SITE WARMTH (Warm to the touch circle at the site of injection) and VACCINATION SITE ERYTHEMA (Red circle at the site of injection). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, ADMINISTRATION SITE INDENTATION (Big circle at the site of injection), VACCINATION SITE WARMTH (Warm to the touch circle at the site of injection) and VACCINATION SITE ERYTHEMA (Red circle at the site of injection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.
This spontaneous report was received from a pharmacist refers to a patient of unknown age and gender. The patient's concurrent conditions, pertinent medical history, concomitant therapies, drug reactions or allergies were not reported. On an unknown date, the patient was vaccinated with VARIVAX, intramuscularly (dose, lot# and expiration date were not reported) for prophylaxis. No adverse symptoms were reported.
This spontaneous report was received from a certified medical assistant and refers to unspecified number of patients of unknown age and gender. There was no information about patients pertinent medical histories, concomitant medications and drug reactions or allergies provided. Since 06-OCT-2015, the patients were vaccinated with improperly stored doses of ROTATEQ orally (lot# L008053, expiration date 30-NOV-2016; lot # L000568, expiration date 10-JUL-2016; lot # L008997, expiration date 04-DEC-2016 dose was not reported). No adverse experiences were reported. This is one of several reports received from the same reporter. Additional information has been requested.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62-year-old male patient received BNT162b2 (BNT162B2), on 10Mar2021 at 18:00 as dose 1, single (Lot number: En6202), in right arm, on 31Mar2021 at 18:00 as dose 2, single (Lot number: Ep6955), in right arm and on 16Jun2022 at 10:00 as dose 4 (booster), single (Lot number: Fn2908) at the age of 62 years, in right arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (COVID-19 VACCINE MODERNA), on 10Nov2021 at 19:00 as dose 3 (booster), single (Lot number: 034f21a), in right arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Negative; Positive; Unknown Result.
This spontaneous report was received from a physician refers to a patient of unknown age and gender. On 06-AUG-2015, the patient was vaccinated with improperly stored PROQUAD (Merck) lot # K025766, expiry date 08-JUN-2015. This is one of the several reports received from the same reporter. Additional information has been requested.
Information has been received from a registered nurse concerning a 22 year old female with penicillin and amoxicillin allergy who on 19-JUN-2008 was vaccinated intramuscularly with the first 0.5 ml dose of GARDASIL (Lot # 660555/0279X) while she was pregnant. Concomitant therapy included ADDERALL TABLETS and oral hormonal contraceptives (unspecified). Her last menstrual period was 15-MAY-2008 and the expected delivery date was 19-JUN-2008. On 31-JUL-2008 the patient had a fetal ultrasound that showed a 10 week and 5 days gestational age fetus with positive cardiac activity. A pregnancy Ultra-screening test was performed with abnormal results. It showed an increased risk, 1 in 10, of having a baby with Down's syndrome. On an unspecified date, the patient elected to terminate this pregnancy. After the pregnancy was terminated, on 25-NOV-2008 the patient received the second dose of GARDASIL (Lot 661764/0650X). Upon internal review, the elected termination of pregnancy was determined to be another important medical event. Additional information has been requested.
On April 3 I had first in lifetime of afib. This May or May not be associated with vaccine. I did have second vaccine on April 10 with no issues. I was hospitalized for 4 days and various tests were performed and I was monitored. In addition I wore a heart monitor for 30 days with no evidence of afib.
Pt recvd 1st & 2nd dose of Recomb on 14MAY90 & 24JUL90 & pt became pregnant: LMP 6SEP90; Pt was twice noted to have a high alpha fetoprotein level; also devel herpes simplex; An ultrasound exam revealed fetus w/in normal limits;
Information has been received from a 66 year old female patient with "allergy to sulfa drugs" who on 24-MAR-2009 was vaccinated with "one dose" of ZOSTAVAX (Merck) (lot number not available). Concomitant therapy included propranolol HCl, ezetimibe, simvastatin (manufacturer unknown) and aspirin. On 24-MAR-2009 "6 hours after receiving ZOSTAVAX (Merck)" the patient developed "pink eye". The patient had not sought medical attention. At the time of reporting the patient's "pink eye" persisted. No further information is available.
No adverse effects reported; improperly stored doses of PROQUAD was administered to the patient; This spontaneous report has been received from an office manager (medical assistant) regarding to a patient of unknown age and gender. The patient's concurrent conditions, medical history, concomitant medication, drug allergies or reaction were not reported.     On 11-APR-2019, the patient was vaccinated with an improperly store dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) (recombinant human albumin, rHA) (lot # R008206 and expiration date 16-SEP-2019) (dose and anatomical location of vaccination was not reported) mixed with a properly stored sterile diluent (DILUENT MRK) for prophylaxis. The administered dose of the vaccine experienced a temperature excursion to 9°C to 25 °C (20.5 °C) for a time frame of 22 hours and 30 minutes. From -9°C to 8°C for 1 hour 15 minutes and -14 °C to -10°C for 1 hour 30 minutes. There was no previous temperature excursion. The call was because of a "data logger". There were no adverse effects reported.   This is one of several report from the same reporter.; Sender's Comments:  US-009507513-1905USA006081: US-009507513-1905USA010084: US-009507513-1905USA010082: US-009507513-1905USA010085: US-009507513-1905USA010080: US-009507513-1905USA010092: US-009507513-1905USA010081:
Vaccination site pain; Stomach aches; Fatigue; Headaches; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Vaccination site pain), ABDOMINAL PAIN UPPER (Stomach aches), FATIGUE (Fatigue) and HEADACHE (Headaches) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037A21B) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-May-2021, the patient experienced VACCINATION SITE PAIN (Vaccination site pain), ABDOMINAL PAIN UPPER (Stomach aches), FATIGUE (Fatigue) and HEADACHE (Headaches). At the time of the report, VACCINATION SITE PAIN (Vaccination site pain), ABDOMINAL PAIN UPPER (Stomach aches), FATIGUE (Fatigue) and HEADACHE (Headaches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       patient was taking concomitant medication which were not provided or unknown.
At facility - tingling & numbness on lips and tongue - predominantly on the left side - this has continued with occasional spreading to nose & eyes & sometimes on other side of face - it waxes & wanes Same day - headache, dizzy, exhausted - lasted 2 days  Next day - nausea, intestinal discomfort - continuing mildly Mild headache continuing
Nervous system alteration, state of anxiety, panic attacks, heart palpitations and severe pain in the chest, lump in the throat, insomnia.
Measles-like rash; antihistamine (no effect). Stopped walking, leg pain.
swelling, redness, warm to touch, sx was reported to have began about 12PM 30APR94; (swelling from just above rt elbow to just below rt shoulder; t101-102;
G62.0 DRUG INDUCED POLYNEUROPATHY 2/11/2022 PANCREATIC CANCER, UNSPECIFIED SITE I26.99 ACUTE PULMONARY EMBOLISM 2/8/2022 PANCREATIC CANCER, UNSPECIFIED SITE G62.0 DRUG INDUCED POLYNEUROPATHY 2/11/2022 PANCREATIC MASS I26.99 ACUTE PULMONARY EMBOLISM 2/8/2022 PANCREATIC MASS G62.0 DRUG INDUCED POLYNEUROPATHY 2/11/2022 PANCREATIC CANCER, UNSPECIFIED SITE I26.99 ACUTE PULMONARY EMBOLISM 2/8/2022 PANCREATIC CANCER, UNSPECIFIED SITE
This spontaneous report as received from a licensed practical nurse refers to two unspecified patients or unknown age and gender. The nurse reported that on 26-JUN-2014 the patients were vaccinated with improperly stored ZOSTAVAX (route and dose were not provided) lot # J014811, expiration date: 21-FEB-2015. No adverse events were reported. This is one of several reports from the same source. Additional information has been requested.
Pregnant patient 8 months post partum states that she stopped lactating after getting the vaccine dose about 8 hours after. She notes that she also started her menstrual cycle soon after this on the same day as the vaccine.
Flu-like symptoms: headache, chills, joint pain, nausea, fatigue
Patinet is a 37 y.o. female ER nurse who received her Covid vaccine just prior to arrival.  While being observed at the vaccine site, she developed itching and a rash.  She was brought down to the ER for evaluation.  Mainly she is itchy all over.  She notes a rash across her chest.  But she has no cough shortness of breath wheezing.  There is no problem swallowing there is no facial swelling.  She does not have a history of anaphylaxis, or medication allergies. Review of Systems  Constitutional: Negative for chills, diaphoresis and fever.  HENT: Negative for congestion, trouble swallowing and voice change.   Eyes: Negative for redness and itching.  Respiratory: Negative for cough, shortness of breath, wheezing and stridor.   Musculoskeletal: Negative for myalgias.  Skin: Positive for rash.       Pruritus  Allergic/Immunologic: Negative for environmental allergies, food allergies and immunocompromised state.  Neurological: Negative for headaches.   01/04/2021- Speaking with the patient she states noticed "hives" accross chest, right lower extremity, and left upper extremity.
Six weeks post vax, pt lab eval revealed lack of seroconversion. This is in follow-up to report(s) previously submitted on 4/15/1998; 5/16/2000. Information has been received from a 28 year old female health care professional with negative VZV titers on 17-APR-1996 who on 07-MAY-1996 and 13-JUN-1996 was vaccinated with the first and second doses of VARIVAX SC in the left and right deltoids, respectively. On 07-AUG-1996 the patient sought unspecified medical attention and another serum VZV antibody test revealed a lack of seroconversion. No further information is available. This is an amended report. The patient's age was changed in the narrative from a "31 year old" to a 28 year old". "Private Doctor/Hospital" was added to the vaccinated at field. "Private Funds" was added to the vaccine purchased with field. This is a corrected report, as amended.
8 days after injection I woke up to large red welps on my arm that were hard and hot.  After having read about "Covid Arm" I knew that was it and it lasted about 9 days.  I had my second shot on 3-12-21 and yesterday (3-14-21) the same thing is happening even though I had the injection in the other arm.
Information has been received from a registered nurse concerning a 52 year old female with hypertension, reactive airway disease and hypercholesterolemia who on 01OCT2003 was vaccinated with a first dose of pneumococcal 23v polysaccharide vaccine. Concomitant medication included albuterol sulfate + Combivent, fish oil, fluticasone propionate + Advair, rofecoxib, hydrochlorothiazide, Losartan potassium and Prevacid. No hx of any rxn to any other vaccination. It was noted that the pt had sinus drainage at the time of vaccination. It was also noted that the vaccination was given to the pt at her cardiologist office. On 02OCT2003 (previously reported as 06OCT2003), the pt was seen in the office with an "injection site huge, size of fist, red, warm", a fever of 103F and was diagnosed with pneumonia. It was also noted that the pt was not hospitalized and was treated with Benadryl, 1 dose "thus far" of Rochepin IM, Augmentin, Tylenol and Ibuprofen. Medical attention was sought. There was no product quality complaint involved. It was noted that the pt recovered form the injection site reaction and the pneumonia. The reporter also mentioned two other pts who were vaccinated with pneumococcal 23v polysaccharide vaccine and experienced similar reactions. No further information is expected.
Patient stated had received Influenza on 11/04/2010 and Pneumoccocal on 11/05/2010. On 11/05/2010 felt chills, redness and soreness on Right arm. Went to urgent care on 11/07/2010 (2 days after symptoms occurred) and was diagnosed with "skin disease" by Dr.
Rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In April 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH (Rash). At the time of the report, RASH (Rash) outcome was unknown.            No concomitant medications were provided. Treatment medications were unknown. Action taken with mRNA-1273 in response to the events was not applicable.
Pt recvd series of 3 Hep B vax in JUL1983; In SEP83 pt had protective levels of antibodies; pt recvd a booster dose w/Engerix-B JAN91 & antibodies were checked in NOV91 & pt did not have protective levels; plans to revax;
I felt the injection burn as it was administered, but I thought nothing of it.  When I sat down my heart rate became elevated almost immediately from 62bpm to 120bpm.  I had flushing that started on my chest, neck and face.  My face was hot to the touch and felt like a sunburn.  My heart rate stayed elevated to 90 bpm for several hours.  When a got back home I then had extreme GI upset.  The flushing stayed warm and red until the following morning.
Patient had acute myocardial infarction 6/8/21, approximately 2.5 months after vaccine.  6 days later (6/14/21) he had CVA.  Following that he has had, per his report, 2 more CVAs (I can find clear documentation of one of those events 6/24/21).  Following that event he had acute pulmonary embolism 9/10/2021 with additional finding of DVT.  Prior to vaccination he had no history of MI, CVA, or DVT/PE
Cold and sweaty hands Intense flushing of face neck and chest Itching and hives on face This occurred about 25 minutes after injection while driving home.  I took chewable Benadryl 12.5 mg  Symptoms slowly resolved with 20 minutes